[DOC] Review of Ruxolitinib for Myelofibrosis Revised final (clean),https://eprints.whiterose.ac.uk/104728/1/Review_of_Ruxolitinib_for_Myelofibrosis_Revised_final_clean_.docx
[DOC] 2021 Casefinding List (Word) - Maine.gov,https://www.maine.gov/dhhs/mecdc/public-health-systems/data-research/vital-records/mcr/hospitals/documents/2021%2520Casefinding%2520List_MCR.docx
[DOC] 1 - NICE,https://www.nice.org.uk/guidance/TA756/documents/97
[DOC] Example for Peginterferon alfa-2a,https://www.hematology.org/-/media/hematology/files/education/clinicians/drugs/letter-of-appeal/peginterferon-appeal-letter.docx
[DOC] united states securities and exchange commission,https://cbc.gcs-web.com/static-files/4a0c9d4d-2933-443f-857b-1106ab143225
[DOC] PRIMARY MYELOFIBROSIS (Balance of Probabilities),http://www.rma.gov.au/assets/SOP/2021/251a58dda2/090.docx
[DOC] Ruxolitinib for the treatment of myelofibrosis: 24 month predicted ...,http://www.pbs.gov.au/industry/listing/participants/public-release-docs/2018-09/ruxolitinib-24-month-review-dusc-prd-2018-09.DOCX
[DOC] 3.3 Relevance to Clinical Practice - CADTH,https://www.cadth.ca/sites/default/files/pcodr/clinician-input/10205Fedratinib_Myelofibrosis_RegisteredClinicianInputTemplate_2020-10-07FINAL.docx
[DOC] Baishideng Publishing Group Inc - F6Publishing,https://www.f6publishing.com/forms/main/DownLoadFile.aspx%3FType%3DDigital%26TypeId%3D2%26id%3D10.12998%252Fwjcc.v10.i9.2931%26FilePath%3D03C6DEC6F3273F9561C42E5EF5FDE5998157E61255F1C13802CE50BF13F0623CCCB336370574861C8B19BB7047E16D3C67DF55BDAF9D3538
[DOC] Attachment 1. Product Information for Ruxolitinib,https://www.tga.gov.au/file/1546/download
